A Remarkable Clinical Response to Pembrolizumab in a Rare Spindle Cell Carcinoma of the Lung
Kyoji Tsurumi(Sendai Kousei Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Shinsuke Yamanda(Sendai Kousei Hospital), Yuichiro Kimura(Tohoku University), Yukihiro Toi(Sendai Kousei Hospital), Atsushi Nakamura(Sendai Kousei Hospital), Yoshihiro Honda, Yosuke Kawashima(Sendai Kousei Hospital), Ryohei Saito(Sapporo Medical University), Jun‐ichi Akahira
Cited by 7
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695